CYTR : Summary for CytRx Corporation - Yahoo Finance

U.S. Markets closed

CytRx Corporation (CYTR)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.41-0.00 (-0.39%)
At close: 4:00PM EDT
People also watch
GALECRISCYCCCTICCVM
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.41
Open0.42
Bid0.21 x 500
Ask0.46 x 500
Day's Range0.39 - 0.42
52 Week Range0.36 - 3.66
Volume648,845
Avg. Volume1,186,673
Market Cap47.54M
Beta1.71
PE Ratio (TTM)-0.65
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • CytRx Corp. :CYTR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
    Capital Cube6 days ago

    CytRx Corp. :CYTR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017

    Categories: Yahoo Finance Get free summary analysis CytRx Corp. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of CytRx Corp. – Amgen Inc., Novartis AG Sponsored ADR, Curis, Inc., GlaxoSmithKline plc Sponsored ADR, Celldex Therapeutics, Inc., Aeolus Pharmaceuticals, Inc., Seattle Genetics, Inc. and Celgene Corporation (AMGN-US, NVS-US, ... Read more (Read more...)

  • PR Newswire12 days ago

    CytRx Reports 2016 Financial Results

    LOS ANGELES, March 15, 2017 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results for the year ...

  • TheStreet.com18 days ago

    The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

    The firms all have drugs they want the feds to bend the rules to approve.